Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Slides:

Advertisements

Similar presentations

Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need

Advertisements

Gerald G Krueger MD Professor, Benning Presidential Endowed Chair

PsO: Review of Available Assessment Instruments and Lessons from Trial Results - Part II Steve Feldman, M.D., Ph.D Professor of Dermatology, Pathology.

EXPRESS: Response Rates at Week Placebo (n=77) Infliximab 5 mg/kg (n=301) Per cent of patients Per cent of patients with.

C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.

1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.

Outcome Measures in PsA Philip Mease MD Seattle, WA.

Number of phototherapy treatments for Psoriasis and Eczema: Audit of data collected at Whipps Cross over a three year period. Jane Watts Senior Nurse Melissa.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.

Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: An Analysis of a Phase 3 Extension Trial in Psoriasis

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single- center experience Ting-Shun Wang, Chih-Chieh Chan, Hsien-Yi Chiu,

Faculty Philip J. Mease, MD

IL-12 and IL-23.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Secukinumab demonstrates significant improvement of disease activity and health related quality of life in Canadian psoriasis patients in a real world.

Clinical Developments in Inflammatory Arthritis 2017

Posters & Abstracts from Amsterdam

From Conference to Practice: Big Data in Psoriasis

Biological Therapy in Psoriasis: Recognizing the Value

Expert Insights on Psoriatic Arthritis From Washington, DC

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

Psoriasis and Comorbidities Psoriasis and Cardiometabolic Comorbidities.

IL-17 Inhibitors in the Management of Psoriatic Disease

Efficacy of simvastatin in plaque psoriasis: A pilot study

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

NICE-BAD clinical audit on psoriasis

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in

Evolving Treatment Landscape for PsA

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

New Data on Emerging Treatments for Psoriasis

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Improving Outcomes in Psoriatic Arthritis

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

The Multifaceted Nature of Psoriasis Addressing Patients' Needs

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis Alexander Egeberg, MD PhD; Mathias Bo Ottosen,

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Understanding How IL-23p19 Inhibitors Work in Psoriasis

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Jennifer L. Hundley, MD, Christie L

Fumaric acid esters in combination with a 6-week course of narrow-band UVB provides for an accelerated response as compared to fumaric acid esters monotherapy.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.

Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis Kyriakou, A. Patsatsi,

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

RCT pilot study comparing localised immersion PUVA with localised narrowband ultraviolet B (NBUVB) for treatment of palmar hand eczema D. Brass1, T.

Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Psoriatic Arthritis.

Presentation transcript:

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Psoriasis Area Severity Index (PASI)

PASI 50, 75, 90

Calculation of PASI

Severity of Psoriatic Lesions

Dermatology Life Quality Index (DLQI)

Scoring DLQI

Physician’s Global Assessment (PGA)

PASI 75 and 90 Responses Achieved With Biologics (2014): Data From Pivotal Phase 3 Studies

Secukinumab Superior to Ustekinumab in Clearing Skin in Moderate-to-Severe Plaque Psoriasis: CLEAR Study 16-Week Results

Secukinumab Phase 3: Robust and Sustained Responses to Week 52

Ixekizumab for Treatment of Moderate-to-Severe Plaque Psoriasis

Improving Magnitude of Response: QoL Is Maximized in Patients Who Achieve PASI 90-100 Response

Secukinumab Phase 3: PASI 90 Provides Rapid and Sustained QoL Improvement Compared With PASI 75-89

Ixekizumab Phase 3 Trials: PASI 100 and PASI 90 Associated With Significantly Improved DLQI vs PASI 75

Improving Long-term Response: Sustained Remission Is a Key Treatment Goal

Some Issues With PASI

Multiple Dimensions

Historical Dimension

Temporal Dimension

Other Factors to Consider

Some Issues With DLQI

DLQI Over a Lifetime Is Worse Than at a Given Point in Time

What Is CLCI?

5 Key Components to CLCI

Coping Strategies Mediate the Effects of Psoriasis

Fundamental Requirements of a New Tool

Simplified Psoriasis Index (SPI)

Learning Points

Abbreviations